M&A
confidence high
sentiment negative
materiality 0.60
CFIUS extends review of Mustang Bio facility sale to uBriGene into second 45-day phase
MUSTANG BIO, INC.
- CFIUS initial 45-day review completed Sep 28, 2023 but not concluded; transitions to second 45-day investigation.
- CFIUS investigation to be completed no later than November 13, 2023.
- Deal involves sale of Mustang's Worcester cell processing facility and manufacturing assets to uBriGene, a Chinese CDMO subsidiary.
- CFIUS clearance was voluntarily submitted and not a condition to closing the transaction.